Pulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
|
|
- Tracy McCormick
- 6 years ago
- Views:
Transcription
1 Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine
2 Pulmonary Circulation Alveolar Capillary relationship
3 Pulmonary Circulation High flow, low resistance PVR ~1/15 of SVR due to large cross-sectional area High capacitance Accommodate CO Arterioles offer very little resistance Systemic arterioles supply 75% total peripheral resistance
4 Determinants of PA Pressure and Flow vascular tone tissue pressure Pcap P PA FLOW P LA P PA = LA + (CO X PVR) Courtesy J. Newman
5 Systemic versus Pulmonary Circulation Systemic Circulation 120/80, mean 93 25/8, mean 14 Systemic Pulmonary Arteries Arteries Pulmonary Circulation Mean 30 RA Mean 2-5 LA Mean 5 Mean 12 Body Lung Systemic Veins RV 25 / 2- LV 120 / 5-10 Pulmonary Veins 5
6 Netter FH. Atlas of Human Anatomy
7 What is Pulmonary Hypertension?? High pressures in the blood vessels responsible for transporting blood from the right-side of the heart to the lungs Impairs the constant flow of blood from the heart to the lungs (Circulatory disorder) Limits the use of oxygen that is breathed into the lungs (Respiratory insufficiency)
8 Definition of Pulmonary HTN Mean Pulmonary Artery Pressure 25 mm Hg (rest) pre-capillary hypertension Pulmonary Vascular Resistance 3 Woods Units (240 dynes/sec/cm 5 ) Trans-pulmonary gradient 12 mm Hg
9 Classification of Pulmonary HTN 2008 Dana Point Pulmonary arterial hypertension (PAH) Idiopathic Heritable Drug & Toxin Associated Pulmonary veno-occlusive Disease and/or capillary hemanigiomatosis Pulmonary hypertension owing to lung diseases and/or hypoxia Chronic obstructive pulmonary disease Interstitial lung diseases Other pulmonary diseases with mixed obstructive & restrictive pattern Sleep-disordered breathing Alveolar hypoventilation disorders Pulmonary hypertension owing to left heart disease Systolic dysfunction Diastolic dysfunction Valvular disease Simonneau G. JACC. 2009; 54: S43-54 Chronic thromboembolic pulmonary HTN Pulmonary hypertension with unclear multifactorial mechanisms Hematologic disorders: splenectomy Systemic disorders: sarcoid, Langerhans cell Metabolic disorders: glycogen storage Others: fibrosing mediastinitis, dialysis
10 Determinants of PA Pressure and Flow vascular tone tissue pressure Pcap P PA Raises vasoconstriction obstruction obliteration flow Compression Lowers vasodilation recruitment FLOW P PA = LA + (CO X PVR) Courtesy J. Newman P LA Raises LVEDP LA venous obstruction blood volume Lowers afterload reduction
11 French Registry: Kaplan-Meier Survival Estimates in Combined PAH Population vs NIH-predicted 100 Observed 80 Survival (%) Predicted (NIH Registry) No. at risk: Time (mo) All patients Humbert M et al. Circulation. 2010;122:
12 BMPR-II Signaling System TGF-β superfamily BMPR-II located on PASMC & Endothelial cells cell inhibition cell differentiation Activate MAPK pathways cell proliferation 25% Sporadic IPAH 75% FPAH 8% Anorexigen-induced 6% CHD PVOD cases Newman JH, et al. NEJM. 2001; 345(5):
13 Archer SL. Circulation. 2010; 121: 2045
14 Vasoactive Substances and the Pulmonary Circulation Constricts HYPOXIA Alpha catecholamine H1 Histamine Serotonin Thromboxanes Leukotrienes Angiotensin Endothelin A (low ph augments) Dilates OXYGEN Beta agonists H2 Histamine Prostacyclins Nitric Oxide (NO) Acetylcholine (NO)
15 Mediators Thromboxane A 2 Endothelin-1 11-Dehydro-thromboxane B 2 (pg/mg of creatinine) 10, P<0.05 Normal Controls (n=14) Patients Patients With With Primary PH Due PH to Other (n=20) Causes (n=8) Patients With CVD- Induced PH (n=6) iret-1 (pg/ml) NS P<0.001 Normal CAD IPAH Christman BW, et al. NEJM. 1992;327: Stewart DJ, et al. Ann Intern Med. 1991;114:464-69
16 Mediators 800 Prostacyclin Nitric Oxide metabolites 2,3-Dinor-6-keto-PGF 1α (pg/mg of creatinine) Normal Controls (n=9) P<0.05 Patients With Primary PH (n=10) Patients With PH Due to Other Causes (n=5) Patients With CVD- Induced PH (n=2) Controls P<0.01 PAH Christman BW, et al. NEJM. 1992;327: Cella G, et al. Chest. 2001;120:
17 Blood Vessel Imbalances NORMAL PULMONARY HYPERTENSION Thromboxane A 2 Endothelin-1 Angiotensin II Serotonin Prostacyclin Nitric oxide ANP / BNP Adrenomedullin Thromboxane A 2 Endothelin-1 Angiotensin II Serotonin Prostacyclin Nitric oxide ANP / BNP Adrenomedullin
18 Homeostatic Imbalances Vasoconstriction Vasodilation Prothrombotic Antithrombotic Proliferation Apoptosis
19 Panvasculoapthy Archer SL. Circulation. 2010; 121: 2045
20 Pathology of PAH WHO Group I: Characterized by progressive growth and vasoconstriction of small pulmonary arteries Gaine S. JAMA. 2000;284:
21 Integrative Pathogenesis Genetic Predisposition Other Risk Factors Altered Pathways and Mediators Proliferation Thrombosis Vasoconstriction Vascular Remodeling
22 Vascular Remodeling Normal PAH high flow low resistance low flow high resistance Adapted from Gaine S. JAMA 2002
23 As PAH Progresses Cardiac Output Declines Pre-symptomatic/ Compensated Symptomatic/ Decompensating Declining/ Decompensated CO Symptom Threshold PAP PVR Right Heart Dysfunction Time
24
25 Does this patient have PAH?? YES NO Treat with PAH specific therapies Optimize underlying condition
26 Right Heart Catheterization
27 PAH Treatment Goals Reverse remodeling >> CURE Improve QOL Prolong survival Prevent hospitalization Delay clinical worsening Lessen symptoms Improve exercise capacity
28 Treatment Pathways Endothelin pathway Endothelin cells Pre-proendothelin Proendothelin Nitric oxide pathway Vessel lumen Prostacyclin pathway Arachidonic acid Prostaglandin I 2 Endothelin receptor A Endothelin receptor antagonist s Endothelin 1 Endothelin receptor B Vasodilation and proliferation L-arginine L-citrulline Phosphodiesterase type 5 Nitric oxide cgmp + Exogenous nitric oxide Vasodilation and antiproliferation Prostacyclin (prostaglandin I 2 ) camp + Vasodilation and antiproliferation Prostacyclin derivatives Smooth muscle cells Phosphodiesteras e type 5 inhibitor Humbert M. N Engl J Med 2004;351:
29 PAH Specific Therapies Therapeutic Class Drug Route of Administration Functional Class Indication Phosphodiesterase 5 - Inhibitors Sildenafil Tadalafil PO II IV II - IV Endothelin Receptor Antagonists Bosentan Ambrisentan PO II IV II - III Iloprost IH III - IV Prostanoid Treprostinil SC*, IV, IH II - IV Epoprostenol IV III - IV *SC Treprostinil only approved for functional class II patients IH treprostinil only approved for FC III patients
30 Prostacyclin Analogues: Intravenous, Subcutaneous, or Inhaled Treprostinil (Remodulin ) Epoprostenol (Flolan or Veletri ) Treprostinil (Remodulin ) Treprostinil (Tyvaso )
31 Flolan (Epoprostenol) Continues infusion (24/7) Potent vasodilator Anti platelet agent Anti proliferative agent Reduces symptoms Prolongs lives
32 Epoprostenol - Hemodynamics L/min/m Cardiac index * * * Baseline Period 1 Period 2 Period 3 mm Hg Mean pulmonary pressure Baseline Period 1 Period 2 Period 3 McLaughlin VV. Circulation 2002;106:
33 Epoprostenol Long Term Sitbon O. J Am Coll Cardiol. 2002;40: McLaughlin VV. Circulation. 2002;106:1477-
34 Treprostinil IV: 6MWD (TRUST) Mean 6MWD (m) Placebo (n=14) Treprostinil IV (n=30) * Mean dose (ng/kg/min) 0 Baseline Week 1 Week 4 Week 8 Week 12 0 *p= MWD values are mean+se. Hiremath J et al. J Heart Lung Transplant. 2010;29:
35 Implantable Pump: Prostanoid Delivery
Pulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationApproach to Pulmonary Hypertension in the Hospital
Approach to Pulmonary Hypertension in the Hospital Todd M Bull MD Professor of Medicine Director Pulmonary Vascular Disease Center Director Center for Lungs and Breathing Division of Pulmonary Sciences
More informationTHERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines
THERAPEUTICS IN PULMONARY ARTERIAL HYPERTENSION Evidences & Guidelines Vu Nang Phuc, MD Dinh Duc Huy, MD Pham Nguyen Vinh, MD, PhD, FACC Tam Duc Cardiology Hospital Faculty Disclosure No conflict of interest
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationRecent Treatment of Pulmonary Artery Hypertension. Cardiology Division Yonsei University College of Medicine
Recent Treatment of Pulmonary Artery Hypertension Cardiology Division Yonsei University College of Medicine Definition Raised Pulmonary arterial pressure (PAP) WHO criteria : spap>40 mmhg NIH Criteria
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationUpdate in Pulmonary Arterial Hypertension
Update in Pulmonary Arterial Hypertension Michael J Sanley, MD April 12, 2018 Disclosures I have nothing to disclose 2 1 Case Presentation 67 yo male with atrial fibrillation, CLL on IVIG, presents with
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.13 Section: Prescription Drugs Effective Date: July 1 2016 Subject: Tyvaso Page: 1 of 4 Last Review
More informationPulmonary Hypertension. Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes
Pulmonary Hypertension Pulmonary Arterial Hypertension Diagnosis, Impact and Outcomes Pulmonary Arterial Hypertension Disease of small pulmonary arteries Characteristic changes Medial hypertrophy Intimal
More informationSotatercept PULSAR Phase 2 PAH Webinar. March 28, 2018
Sotatercept PULSAR Phase 2 PAH Webinar March 28, 2018 Acceleron Forward-Looking Statements THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS ABOUT THE COMPANY S STRATEGY, FUTURE PLANS and prospects,
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.21 Subject: Orenitram Page: 1 of 6 Last Review Date: June 24, 2016 Orenitram Description Orenitram
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.10 Subject: Uptravi Page: 1 of 6 Last Review Date: September 15, 2017 Uptravi Description Uptravi
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.17 Subject: Remodulin Page: 1 of 5 Last Review Date: June 24, 2016 Remodulin Description Remodulin
More informationPulmonary arterial hypertension. Pulmonary arterial hypertension: newer therapies. Definition of PH 12/18/16. WHO Group classification of PH
Pulmonary arterial hypertension Pulmonary arterial hypertension: newer therapies Ramona L. Doyle, MD Clinical Professor of Medicine, UCSF Attending Physician UCSF PH Clinic Definition and classification
More informationPatient Case. Patient Case 6/1/2013. Treatment of Pulmonary Hypertension in a Community
Treatment of Pulmonary Hypertension in a Community Hospital Serena Von Ruden, PharmD, RN, BSN St. Francis Hospital Federal Way, WA Franciscan Health System HPI: 66 year old male with advanced oxygendependent
More informationA Best Practices Approach to Treating Pulmonary Hypertension for the ED and Acute Care Provider. Disclosures
A Best Practices Approach to Treating Pulmonary Hypertension for the ED and Acute Care Provider Sean M. Studer, MD, MSc Chief, Pulmonary & Critical Care Director, Pulmonary Hypertension & Lung Transplantation
More informationPharmacy Management Drug Policy
SUBJECT: Pulmonary Arterial Hypertension (PAH) POLICY NUMBER: Pharmacy-42 Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed
More informationMACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH)
MACITENTAN DEVELOPMENT IN CHILDREN WITH PULMONARY HYPERTENSION (PAH) ORPHAN DRUG AND RARE DISEASE 11 MAY 2017 Catherine Lesage, MD, Pediatrics Program Head, Actelion Copyright AGENDA Pulmonary Arterial
More informationADVANCED THERAPIES FOR PHARMACOLOGICAL TREATMENT OF PULMONARY HYPERTENSION
Status Active Medical and Behavioral Health Policy Section: Medicine Policy Number: II-107 Effective Date: 04/21/2014 Blue Cross and Blue Shield of Minnesota medical policies do not imply that members
More informationADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationAdvances in Pharmacotherapy of PAH
24 th Annual Advances in Heart Disease Advances in Pharmacotherapy of PAH Gabriel Gregoratos, MD 12/14/2007 UCSF Cardiology 1 Faculty Disclosure Statement for Gabriel Gregoratos, MD Nothing to disclose
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.15 Subject: Flolan Veletri Page: 1 of 5 Last Review Date: September 15, 2017 Flolan Veletri Description
More informationREVATIO (sildenafil)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Health Technology Appraisal. Drugs for the treatment of pulmonary arterial hypertension
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Health Technology Appraisal Drugs for the treatment of Draft remit / appraisal objective: Draft scope To appraise the clinical and cost effectiveness
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationPulmonary Hypertension: Definition and Unmet Needs
Heart Failure Center Hadassah University Hospital Pulmonary Hypertension: Definition and Unmet Needs Israel Gotsman The Heart Failure Center Hadassah University Hospital I DO NOT have a financial interest/
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.16 Subject: Letairis Page: 1 of 6 Last Review Date: June 24, 2016 Letairis Description Letairis (ambrisentan)
More information4/14/2010. Pulmonary Hypertension: An Update. Tim Williamson, MD, FCCP. University of Kansas Hospital. Normal Physiology
Pulmonary Hypertension: An Update Tim Williamson, MD, FCCP Director, Pulmonary Vascular Program University of Kansas Hospital Normal Physiology 1 Pulmonary Perfusion 101 High Pressure Low Pressure Pulmonary
More information1. Phosphodiesterase Type 5 Enzyme Inhibitors: Sildenafil (Revatio), Tadalafil (Adcirca)
This policy has been developed through review of medical literature, consideration of medical necessity, generally accepted medical practice standards, and approved by the IEHP Pharmacy and Therapeutic
More informationUpdate on pulmonary HTN
Update on pulmonary HTN Feras Bader, MD, MS, FACC Associate Professor of Medicine- Cardiology University of Utah School of Medicine Director, Advanced Heart Failure and Transplant Program Dabbous Cardiac
More informationPulmonary Hypertension: When to Initiate Advanced Therapy. Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University
Pulmonary Hypertension: When to Initiate Advanced Therapy Jonathan D. Rich, MD Associate Professor of Medicine Northwestern University Disclosures Medtronic, Abbott: Consultant Hemodynamic Definition of
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.23 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: September 15, 2017 Sildenafil
More informationPDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder
RATIONALE FOR INCLUSION IN PA PROGRAM Background Sildenafil and Tadalafil are marketed as Revatio and Adcirca for pulmonary arterial hypertension. This is a rare disorder of the pulmonary arteries in which
More informationIdentifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension
Identifying Appropriate Treatment & Management Strategies in Pulmonary Arterial Hypertension Harold I. Palevsky, M.D. Perelman School of Medicine of the University of Pennsylvania Penn Presbyterian Medical
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationPulmonary Arterial Hypertension - Overview
Pulmonary Arterial Hypertension - Overview J. Shaun Smith, MD Co-Director, Pulmonary Vascular Disease Program Assistant Professor of Medicine Division of Pulmonary, Critical Care and Sleep Medicine The
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationCurrent and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06
Current and Emerging Drugs in Pulmonary Vascular Pharmacology Dr AS Paul DM Seminar 08 September 06 Pulmonary Hypertension A mean pressure of greater than 25 mm Hg at rest (normal ~14 mm Hg) or greater
More informationINPATIENT USE OF PARENTERAL PROSTACYCLINS IN AN ACADEMIC MEDICAL CENTER
INPATIENT USE OF PARENTERAL PROSTACYCLINS IN AN ACADEMIC MEDICAL CENTER Maria Guido, PharmD, BCPS Clinical Pharmacy Specialist Internal Medicine University of Cincinnati Medical Center OSHP 77 th Annual
More informationPulmonary Arterial Hypertension: The Approach to Management in 2019
Pulmonary Arterial Hypertension: The Approach to Management in 2019 Munir S. Janmohamed M.D. FACC Medical Director Mechanical Circulatory Support/Heart Failure Program Mercy General Hospital/Mercy Medical
More informationTherapeutic Categories Outlook
Equity Research Health Care Therapeutic Categories Outlook Comprehensive Study February 2017 Alzheimer s Disease Bone Diseases Cardiovascular Central Nervous System Dermatology Diabetes/Obesity Epilepsy
More informationClinical Policy: Macitentan (Opsumit) Reference Number: ERX.SPMN.88
Clinical Policy: (Opsumit) Reference Number: ERX.SPMN.88 Effective Date: 07/16 Last Review Date: 06/16 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationPULMONARY ARTERIAL HYPERTENSION AGENTS
Approvable Criteria: PULMONARY ARTERIAL HYPERTENSION AGENTS Brand Name Generic Name Length of Authorization Adcirca tadalafil Calendar Year Adempas riociguat Calendar Year Flolan epoprostenol sodium Calendar
More informationPharmacy Coverage Guidelines are subject to change as new information becomes available.
SILDENAFIL oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage Guideline
More informationΕιδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών
Ειδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών . Updated Clinical Classification of Pulmonary Hypertension
More informationPULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER
PULMONARY HYPERTENSION RESPIRATORY & CRITICAL CARE CONFERENCE APRIL 21, 2016 LAURA G. HOOPER OUTLINE Brief review of WHO Group Classification Scheme Subgroups we ll focus on: WHO Group I Pulmonary Arterial
More informationUpdates in Pulmonary Hypertension Pharmacotherapy. Ziad Sadik PharmD BCPS
Updates in Pulmonary Hypertension Pharmacotherapy Ziad Sadik PharmD BCPS Disclosure Information I have no financial relationship to disclose AND I will not discuss off label use and/or investigational
More informationRole of Combination PAH Therapies
Role of Combination PAH Therapies Ronald J. Oudiz, MD, FACP, FACC Associate Professor of Medicine, David Geffen School of Medicine at UCLA Director, Liu Center for Pulmonary Hypertension Los Angeles Biomedical
More informationObjectives. Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease
Disclosures Oral Therapies for Children with Pulmonary Hypertensive Vascular Disease Erika Berman Rosenzweig, MD Director, Pulmonary Hypertension Center Associate Professor of Clinical Pediatrics (in Medicine)
More informationClinical Policy: Ambrisentan (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16
Clinical Policy: (Letairis) Reference Number: ERX.SPMN.84 Effective Date: 07/16 Last Review Date: 06/16 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationPulmonary Hypertension: Evolution and
Management of Pulmonary Hypertension: Evolution and Controversies VERMONT CARDIAC NETWORK SPRING CONFERENCE MAY 10, 2018 MARYELLEN ANTKOWIAK, MD, PULMONARY & CRITICAL CARE MEDICINE, UVMMC WHO classification
More informationDisclosures. Inhaled Therapy in Pediatric Pulmonary Hypertension. Inhaled Prostacyclin: Rationale. Outline
Disclosures Inhaled Therapy in Pediatric Pulmonary Hypertension The University of Colorado receives fees for Dr Ivy to be a consultant for Actelion, Gilead, Lilly, Pfizer, and United Therapeutics Dunbar
More informationThe Circle of New Life for Pulmonary Hypertension Patients: Where does Palliative Care have a role in the new treatment era?
The Circle of New Life for Pulmonary Hypertension Patients: Where does Palliative Care have a role in the new treatment era? { Kenneth Presberg, MD Professor of Medicine Director, PHA Comprehensive Pulmonary
More informationPharmacy Management Drug Policy
SUBJECT: POLICY NUMBER: PHARMACY-42 EFFECTIVE DATE: 6/2005 LAST REVIEW DATE: 4/19/2018 If the member s subscriber contract excludes coverage for a specific service or prescription drug, it is not covered
More informationΠνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ
Πνευμονική Υπέρταση Ι.Ε. ΚΑΝΟΝΙΔΗΣ PH is defined as PAPm 25 mm Hg at rest The general definition of PH remains unchanged Most of the relevant epidemiological and therapeutic studies have used the 25 mm
More informationTherapeutic approaches in P(A)H and the new ESC Guidelines
Therapeutic approaches in P(A)H and the new ESC Guidelines Jean-Luc Vachiéry, FESC Head Pulmonary Vascular Diseases and Heart Failure Clinic Hôpital Universitaire Erasme Université Libre de Bruxelles Belgium
More informationDisclosures. Objectives 6/16/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension Susan P. D Anna MSN, APN-BC, CHFN June 24, 2016 Disclosures Objectives Differentiate structure and function of RV and LV
More informationPulmonary Arterial Hypertension in Pa)ents with HIV Infec)on: New Thoughts, BeGer Outcomes
Pulmonary Arterial Hypertension in Pa)ents with HIV Infec)on: New Thoughts, BeGer Outcomes Hap Farber, MD Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures Consultant:
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tracleer Page: 1 of 6 Last Review Date: September 15, 2017 Tracleer Description Tracleer (bosentan)
More informationTreprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan
CHEST Treprostinil-Based Therapy in the Treatment of Moderate-to-Severe Pulmonary Arterial Hypertension* Long-term Efficacy and Combination With Bosentan Raymond L. Benza, MD; Barry K. Rayburn, MD; Jose
More informationPhosphodiesterase Type 5 Inhibitors: ADCIRCA (tadalafil) oral tablet REVATIO (sildenafil) oral suspension and tablet
REVATIO (sildenafil) oral suspension and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This
More informationTeaching Round Claudio Sartori
Teaching Round 14.03.2017 Claudio Sartori Cas clinique Femme 47 ans, connue pour un BPCO, asthénie, douleurs thoraciques, dyspnée à l effort, œdèmes membres inférieurs, deux syncopes. Tabac, BMI 31 kg/m2
More informationRecruitment and Consenting
1 Recruitment and Consenting MOP Chapter 4 NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health with support from
More informationPULMONARY HYPERTENSION For Cardiologists
PULMONARY HYPERTENSION For Cardiologists Pulmonary Hypertension Classification Pulmonary Hypertension General Definition Resting Systolic PAP Resting Diastolic PAP Resting Mean PAP > 35mmHg > 15mmHg >
More informationPulmonary Vasodilator Treatments in the ICU Setting
Pulmonary Vasodilator Treatments in the ICU Setting Lara Shekerdemian Circulation 1979 Ann Thorac Surg 27 Anesth Analg 211 1 Factors in the ICU Management of Pulmonary Hypertension After Cardiopulmonary
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationCombination therapy in the treatment of pulmonary arterial hypertension 2015 update
Journal of Rare Cardiovascular Diseases 2015; 2 (4): 103 107 www.jrcd.eu REVIEW ARTICLE Rare diseases of pulmonary circulation Combination therapy in the treatment of pulmonary arterial hypertension 2015
More informationPulmonary vascular remodelling: causes, mechanisms and consequences
Pulmonary vascular remodelling: causes, mechanisms and consequences Ralph Schermuly Department of Pulmonary Pharmacotherapy University of Giessen and Marburg Lung Center email: ralph.schermuly@ugmlc.de
More informationACCP PAH Medical Therapy Guidelines: 2007 Update. David Badesch, MD University of Colorado School of Medicine Denver, CO
ACCP PAH Medical Therapy Guidelines: 2007 Update David Badesch, MD University of Colorado School of Medicine Denver, CO Disclosure of Commercial Interest Dr. Badesch has received grant/research support
More informationPulmonary Hypertension and Left Heart Disease: What s good for the goose is not necessary good for the gander
Pulmonary Hypertension and Left Heart Disease: What s good for the goose is not necessary good for the gander Jacqueline Fearon-Clarke, MA, ACNP-BC Heart Failure and Pulmonary Hypertension Nurse Practitioner
More informationCase Study Investigation (CSI) Diagnosis and Management of Pulmonary Arterial Hypertension Case Review Monograph. editor
PAH Case Study Investigation (CSI) Diagnosis and Management of Pulmonary Arterial Hypertension Case Review Monograph editor Harrison W. Farber, MD Professor of Medicine Director, Pulmonary Hypertension
More informationPulmonary Arterial Hypertension: Biomarkers and Treatment
Pulmonary Arterial Hypertension: Biomarkers and Treatment Demos Papamatheakis, MD Assistant Clinical Professor Division of Pulmonary, Critical Care and Sleep Medicine UC San Diego Health Definition EHJ
More informationReferral Forms for TYVASO and REMODULIN
Referral Forms for TYVASO and REMODULIN HOW TO GET STARTED Tyvaso and Remodulin are available only through select Specialty Pharmacy Services (SPS) providers. Follow these 5 simple steps to complete each
More informationPaediatric PAH in the current era
Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The
More informationDisclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
Disclosures A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension No financial relationships Susan P. D Anna MSN, APN BC, CHFN September 29, 2016 Objectives RV vs LV Differentiate
More informationOral Therapies for Pulmonary Arterial Hypertension
Oral Therapies for Pulmonary Arterial Hypertension Leslie Wooten, PharmD PGY2 Internal Medicine Pharmacy Resident University of Cincinnati Medical Center April 30 th, 2018 Objectives Pharmacist Objectives
More informationPulmonary Hypertension in Chronic Obstructive Pulmonary Disease
Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Deedre Boekweg RN, BSN, CCRP Intermountain Medical Center Murray, UT Kerri Akaya Smith, MD University of Pennsylvania Philadelphia, PA PHPN
More informationAdvanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension. Original Policy Date
MP 5.01.07 Advanced Therapies for Pharmocological Treatment of Pulmonary Arterial Hypertension Medical Policy Section Prescription Drug Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date
More informationPulmonary Hypertension: Classification
Pulmonary Hypertension: Pathophysiology and Classification M. Maggiorini Medical Intensive Care Unit University Hospital Zürich Pulmonary hypertension is a disease of the pulmonary circulation with many
More informationBosentan for treatment of pulmonary arterial hypertension (I)
KEY PAPER EVALUATION Bosentan for treatment of pulmonary arterial hypertension (I) Sabina A Antoniu University of Medicine and Pharmacy, Clinic of Pulmonary Disease, 62 Costache Negri St, Bl.C2, Sc.A,
More informationFiltering through the Facts: Portopulmonary Hypertension Saturday, September 19, :15 10:05 a.m.
Filtering through the Facts: Portopulmonary Hypertension Saturday, September 19, 2015 9:15 10:05 a.m. Joel Wirth, MD Pulmonary & Critical Care Medicine Maine Medical Center, Portland, ME Disclosures Dr.
More informationWednesday, April 25 Screening Diagnosis and Treatment of PAH: An Overview
Wednesday, April 25 Screening Diagnosis and Treatment of PAH: An Overview Kerri Akaya Smith, MD Screening, Diagnosis, and Treatment of Pulmonary Arterial Hypertension (PAH): An Overview New Jersey Association
More informationNational Horizon Scanning Centre. Tadalafil for pulmonary arterial hypertension. October 2007
Tadalafil for pulmonary arterial hypertension October 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationChronic Thromboembolic Pulmonary Hypertention CTEPH
Chronic Thromboembolic Pulmonary Hypertention CTEPH Medical Management Otto Schoch, Prof. Dr. Klinik für Pneumologie und Schlafmedizin Kantonsspital St.Gallen CTEPH: Medical Management Diagnostic aspects
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency London, 18 December 2008 Doc. Ref. EMEA/CHMP/EWP/356954/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT CHMP GUIDELINE ON THE CLINICAL INVESTIGATIONS OF MEDICINAL
More informationReview Article Diagnosis and Management of Pulmonary Arterial Hypertension
Pulmonary Medicine Volume 2011, Article ID 845864, 13 pages doi:10.1155/2011/845864 Review Article Diagnosis and Management of Pulmonary Arterial Hypertension Jeanne Houtchens, Douglas Martin, and James
More informationSildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.15 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: December 3, 2015 Sildenafil Citrate
More informationProgress in PAH. Gerald Simonneau
Progress in PAH Gerald Simonneau National Reference center for Pulmonary Hypertension Bicetre University Hospital, INSERM U 999 Paris-Sud University Le Kremlin Bicêtre France Clinical Classification of
More informationPulmonary Arterial Hypertension (PAH) Treatments
Care1st Health Plan Arizona, Inc. Easy Choice Health Plan Harmony Health Plan of Illinois Missouri Care Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona OneCare (Care1st Health
More informationThe Hemodynamics of PH Interpreting the numbers
The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationIV PGI2 vs. Inhaled PGI2 in chronic lung disease
Inhaled Therapies for PAH Erika Berman Rosenzweig, MD Associate Professor of Clinical Pediatrics (in Medicine) Director, Pulmonary Hypertension Center Columbia University Medical Center Disclosures Has
More information